Saturday 17 October 2026
Export ATRA’s income statement to Excel — free account
Atara Biotherapeutics, Inc.
ATRA Healthcare Biotechnology
Atara Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $120.8 million, down 6.33% from fiscal 2024. In the quarter to June 2026, revenue fell 96.4%, EPS fell 260.0% and free cash flow grew 52.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
9.18
0.47
−4.87%
Follow ATRA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 5.72 | 6.46 |
+8 more quarters Free account |
P/S ratio |
27.86 | 2.88 | 1.88 | 1.28 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(51.70) | (21.67) | (39.83) | (19.86) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
26.27 | 2.52 | 1.81 | 1.19 | |
EV/EBITDA |
0.00 | 0.00 | 5.71 | 6.15 | |
EV/Operating CF |
(7.43) | (2.25) | (4.29) | (2.59) | |
EV/FCF |
(7.73) | (2.33) | (4.36) | (2.60) | |
Quick Ratio |
1.49 | 1.48 | 0.65 | 0.87 | |
Current Ratio |
1.98 | 2.16 | 0.82 | 1.02 | |
Net Debt/EBITDA |
2.09 | 2.50 | 3.49 | 3.79 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.21 | 0.56 | 1.87 | 1.76 | |
Operating CF/Net income |
0.69 | 0.74 | 1.67 | 2.27 | |
Capex/Depreciation |
0.00 | 0.00 | 4.17 | (0.94) | |
Interest Coverage |
(24.71) | (4.06) | (2.87) | (3.93) | |
Research and Development Expense of Revenue |
213.49% | 31.78% | (13.98%) | 84.71% | |
Selling, General and Administrative Expense of Revenue |
605.40% | 697.09% | 268.15% | 115.46% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
62.54% | 145.16% | 95.11% | 35.48% | |
Graham Net Nets |
(0.26) | (0.68) | (0.20) | (0.25) | |
Graham Number |
8.08 | 6.27 | 0.00 | 0.00 | |
Earnings Yield |
(10.28%) | (13.95%) | 17.47% | 15.49% | |
Free Cash Flow Yield |
(12.19%) | (37.56%) | (22.07%) | (35.71%) | |
Revenue per Share |
0.04 | 0.04 | 0.13 | 0.25 | |
Operating CF per Share |
(0.22) | (0.22) | (0.45) | (0.72) | |
Capex per Share |
0.00 | 0.00 | 0.04 | 0.00 | |
Free Cash Flow per Share |
(0.22) | (0.22) | (0.41) | (0.72) | |
Cash per Share |
0.66 | 0.59 | 0.68 | 1.01 | |
Shareholders Equity per Share |
(2.46) | (2.65) | (3.07) | (2.70) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.46) | (2.65) | (3.07) | (2.70) | |
Free Cash Flow |
(3.34) | (3.07) | (5.14) | (9.74) | |
Working Capital |
6.68 | 6.53 | (2.71) | 0.38 | |
Capital Expenditures |
— | — | 0.56 | 0.04 | |
Net Current Asset Value |
(44.49) | (45.14) | (46.52) | (48.37) | |
EV/EBIT |
0.00 | 0.00 | 6.09 | 6.89 | |
Capex to Sales |
0.00 | 0.00 | (0.35) | (0.01) | |
Price to Operating Income |
0.00 | 0.00 | 6.33 | 7.41 | |
| Other line items | |||||
Average Receivables |
0.90 | — | 1.29 | 2.17 | |
Average Payables |
1.29 | 1.01 | 2.25 | 1.23 | |
Average Assets |
28.96 | 41.02 | 64.67 | 86.44 | |
Average Common Equity |
(36.02) | (46.19) | (67.89) | (63.59) |
Columns are period end dates